Scott E Conard

Summary

Publications

  1. ncbi Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Lipids Health Dis 9:136. 2010
  2. ncbi Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease
    Scott E Conard
    University of Texas Southwestern Medical School, Dallas, TX, USA
    Am J Cardiol 102:1489-94. 2008
  3. ncbi Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
    S Conard
    Family Practice, University of Texas Southwestern Medical School, Dallas, TX 75243, USA
    Diabetes Obes Metab 12:210-8. 2010

Detail Information

Publications3

  1. ncbi Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
    Harold Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
    Lipids Health Dis 9:136. 2010
    ....
  2. ncbi Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease
    Scott E Conard
    University of Texas Southwestern Medical School, Dallas, TX, USA
    Am J Cardiol 102:1489-94. 2008
    ....
  3. ncbi Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
    S Conard
    Family Practice, University of Texas Southwestern Medical School, Dallas, TX 75243, USA
    Diabetes Obes Metab 12:210-8. 2010
    ..Thus, it is useful to know the relative efficacy of lipid-altering drugs in these patient populations...